Dyadic International (DYAI) Corporate presentation summary

Market opportunity and challenges

• Global demand for animal-free proteins is rising, driven by sustainability and advanced biologics needs.

• Existing production systems face high costs, supply chain vulnerabilities, and limited manufacturing capacity.

• Sustainability pressures and resource-intensive processes challenge traditional biologics manufacturing.

Platform technologies and advantages

• C1 and Dapibus platforms enable rapid strain development, high-yield fermentation, and animal-free production.

• Platforms support scalable production from 1L to over 100,000L, with proven commercial manufacturing.

• Humanized glycosylation and flexible microbial systems allow for broad protein expression and simplified purification.

• Non-sporulating strains reduce contamination risk and simplify GMP operations.

Product applications and performance

• C1 platform supports high-yield production of complex biologics, including vaccines, monoclonal antibodies, and animal health products.

• Demonstrated productivity exceeds 20 g/L for vaccine antigens and antibodies, with human-like glycan structures.

• Commercial product portfolio includes animal-free proteins for cell culture, diagnostics, and nutrition.